Century Therapeutics, Inc. develops induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases, including type 1 diabetes, and cancer. Its platform uses an iPSC cell foundry and Allo-Evasion™ immune-evasion engineering to create allogeneic beta islet, T cell and natural killer cell programs, including CNTY-813 for type 1 diabetes and CD19-targeted CAR-iT work such as CNTY-308.
Recurring company updates address preclinical data presentations, regulatory-pathway disclosures, financial results, investor presentations, board and committee changes, and collaboration economics tied to the company’s collaboration, option and license agreement with Bristol-Myers Squibb.
Century Therapeutics (NASDAQ: IPSC) reported Q4 and full-year 2021 results, ending with $358.8 million in cash, ensuring operations into 2025. A strategic collaboration with Bristol Myers Squibb includes a $100 million upfront payment and a $50 million equity investment. The company plans to submit an IND for CNTY-101 in mid-2022 and initiate the Phase 1 ELiPSE-1 trial for relapsed/refractory lymphoma. R&D expenses rose to $75.6 million, contributing to a net loss of $95.8 million for 2021. The company anticipates operating expenses between $155 million and $165 million for 2022.
Century Therapeutics (NASDAQ: IPSC) announced that its senior management team will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 1:40 PM ET. A live webcast of the event will be accessible on Century's website and available for replay for 90 days. The company focuses on developing induced pluripotent stem cell (iPSC)-derived cell therapies for cancer, aiming to address the limitations of traditional cell therapies and enhance patient access.
Bristol Myers Squibb (NYSE:BMY) reported Q4 revenues of $12.0 billion, an 8% increase driven by robust sales of Eliquis and immuno-oncology products. Full-year revenues reached $46.4 billion, up 9%. Q4 earnings per share (EPS) stood at $1.07 (GAAP) and $1.83 (non-GAAP), with annual EPS at $3.12 and $7.51 respectively. The company announced a $15 billion share repurchase authorization and provided 2022 guidance, predicting $47 billion in revenues. The outlook includes expected growth from new products and a reduction in operating expenses.
Bristol Myers Squibb (NYSE:BMY) has reported fourth quarter revenues of $12.0 billion, marking an 8% increase year-over-year, and full-year revenues of $46.4 billion. The fourth quarter earnings per share (EPS) stand at $1.07 (GAAP) and $1.83 (non-GAAP), with full-year EPS at $3.12 and $7.51 respectively, reflecting a 17% growth in non-GAAP EPS. The company has authorized a $15 billion share repurchase initiative and announced a $5 billion accelerated share repurchase agreement for Q1 2022. Guidance for 2022 includes projected revenues of approximately $47 billion.
Century Therapeutics (NASDAQ: IPSC) and Bristol Myers Squibb (NYSE: BMY) have formed a collaboration to develop iPSC-derived cell therapies for hematologic malignancies. Century will receive an upfront payment of $100M and a $50M equity investment, with a total of up to $3B in potential milestone payments and royalties. The initial projects focus on acute myeloid leukemia and multiple myeloma. Bristol Myers Squibb will lead clinical development, while Century retains co-promotion rights. This partnership aims to leverage expertise in oncology and enhance the chances of successful outcomes.
Century Therapeutics (NASDAQ: IPSC) and Bristol Myers Squibb (NYSE: BMY) have announced a collaboration to develop allogeneic cell therapies targeting hematologic malignancies and solid tumors. Century will receive $150M, including $100M upfront and a $50M equity investment. Additional payments could exceed $3B based on program milestones. The first two programs focus on acute myeloid leukemia and multiple myeloma, leveraging Century's innovative iPSC technology.
On January 4, 2022, Century Therapeutics (NASDAQ: IPSC) announced that its CEO, Lalo Flores, Ph.D., will present virtually at the 40th Annual J.P. Morgan Healthcare Conference on January 11, 2022, at 1:30 PM ET. The event will cover the company's advancements in iPSC-derived cell therapies for cancer treatment. A live webcast will be available on the company’s website, with a replay accessible for 30 days afterward. Century Therapeutics focuses on harnessing stem cells to improve patient care in oncology.
Century Therapeutics (NASDAQ: IPSC) has been selected for inclusion in the NASDAQ Biotechnology Index (NASDAQ: NBI), effective December 20, 2021. This index tracks companies in the biotechnology and pharmaceuticals segment, requiring a minimum market capitalization of $200 million and an average trading volume of at least 100,000 shares. Being part of the index can enhance visibility and attract institutional investments. Century Therapeutics focuses on developing iPSC-derived cell therapies targeting cancers, aiming to facilitate broader patient access and improve cancer treatment outcomes.
Century Therapeutics (NASDAQ: IPSC) presented promising preclinical data for its CNTY-101 program at the ASH Annual Meeting, showing strong antitumor activity against human lymphoma cell lines. The company plans to initiate the Phase 1 ELiPSE-1 trial for CNTY-101 in relapsed/refractory lymphoma with an IND submission on track for mid-2022. The data support the use of γδ CAR-iT cells, which do not present a GVHD risk, marking a significant advancement in their iPSC-derived T cell therapies.
Century Therapeutics (NASDAQ: IPSC) announced the participation of its senior management in a fireside chat ahead of the Piper Sandler 33rd Annual Virtual Healthcare Conference, scheduled for November 30 to December 2, 2021. A recording of the chat will be available today at 10:00 AM ET on the Events & Presentations section of Century's website, accessible for 30 days. The company focuses on developing iPSC-derived cell therapies aimed at overcoming challenges in cancer treatment.